CURE’s gastric cancer page is a go-to resource for oncology news and updates in the world of gastric cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in gastric cancer.
January 24th 2022
Patients with gastric cancer who present with certain bacteria in their gut were found to be more likely to experience skin-related side effects from Opdivo treatment, research showed.
January 21st 2022
The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer.
January 18th 2022
The FDA will speed up their review of CYNK-101 plus chemotherapy and immune checkpoint inhibitors for the treatment of advanced HER2-postivie gastric or gastroesophageal adenocarcinomas.
December 30th 2021
From nurse navigators to surgeons, clinical social workers and more, a patient with cancer often has a village of team members helping them achieve a smooth and successful treatment experience.
December 22nd 2021
Communication, self-advocacy and having someone in your corner are all critical tools to bring to a cancer care visit, says an expert from MedStar Georgetown University Hospital.
December 18th 2021
There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.
November 4th 2021
The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.
August 31st 2021
Aprepitant, palonosetron and dexamethasone curbed chemotherapy-induced nausea and vomiting in certain women with gastrointestinal cancers who were receiving FOLFIRI or FOLFOX regimens.
August 17th 2021
The indication for the PD-1 blocking antibody now includes adults with mismatch repair-deficient recurrent or advanced disease, adding to the previous indication of endometrial solid tumors.
August 13th 2021
On behalf of Hope for Stomach Cancer, Dr. Yanghee Woo speaks with CURE® about risk factors for gastric cancer and the alarming rise in cases in young adults.
August 6th 2021
Knowing they’ve inherited a genetic mutation for stomach or breast cancer gives patients the power to plan ahead.
July 23rd 2021
The FDA’s recent approval of Keytruda in combination with trastuzumab and chemotherapy in the first-line setting is an exciting change for a group of patients with certain subtypes of stomach cancer, according to an expert.
July 20th 2021
As patients aged 65 or older receive a diagnosis of cancer, their treatment course and priorities may differ from their younger counterparts.
June 28th 2021
Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.
June 5th 2021
Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.
May 20th 2021
Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this occurred.
May 5th 2021
Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.
April 16th 2021
The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.
March 21st 2021
In clinical trials, Opdivo in combination with chemotherapy improved overall survival and progression-free survival compared to chemotherapy alone.
February 10th 2021
Theresa Germano sat down with HEAL® to discuss her journey with cancer, how her daughter became her hero and how listening to her body benefited her in the end.
January 21st 2021
For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.
January 20th 2021
The priority review will focus on Opdivo with chemotherapy for the treatment several gastrointestinal cancers, which has recently become a rising area in novel treatment development.
January 16th 2021
In an interview with CURE®, expert Martha Raymond explains the importance of clinical trials during the COVID-19 pandemic and how clinicians must find a way to help ease patients anxieties as they return to the clinic.
January 15th 2021
The Food and Drug Administration approved Enhertu to treat adults with locally advanced or metastatic HER2-positive gastroesophageal or gastric cancer who have previously received a trastuzumab-based treatment regimen.
December 22nd 2020
The FDA granted a priority review to the supplemental biologics license application for the combination of Keytruda and chemotherapy for the firstline treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.
November 11th 2020
I am a nurse practitioner and a professor. But my best job was being a daughter and caregiver to the most wonderful mother anyone could ever have.
October 15th 2020
Join us for our Inaugural 1st Hope Webcast on surgical strategies for Stage IV stomach cancer.
September 17th 2020
Cancer makes your mind wander in many strange directions. If ever you wanted to know what an emotional rollercoaster really felt like, get on the cancer coaster and go for a ride.
September 8th 2020
Patients, caregivers, and families to gain virtual access to the latest topics in gastric cancer research from oncology experts.